MRNA RATIOS IN URINARY SEDIMENTS AND/OR URINE AS A PROGNOSTIC AND/OR THERANOSTIC MARKER FOR PROSTATE CANCER
摘要
Described herein are methods and kits for prognosis of prostate cancer in a subject. The methods comprises: (a) determining the ratio of PCA3 and PSA expression in a urine sample and (b) correlating the value of the PCA3/PSA ratio with the aggressiveness and mortality risk of prostate cancer in the subject. Kits for prognosing prostate cancer are also described. More particularly, the present invention features a method for prognosing prostate cancer in a biological sample of a patient comprising: assessing the amount of a prostate cancer specific PCA3 mRNA and the amount of PSA in the biological sample; determining a ratio value of this amount of prostate cancer specific PCA3 mRNA over the amount of PSA; comparing the ratio value to at least one predetermined cut-off value, wherein a ratio value above the predetermined cut-off value is indicative of a higher risk of mortality of prostate cancer as compared to a ratio value below the predetermined cut-off value.
申请公布号
CA2594125(A1)
申请公布日期
2006.06.29
申请号
CA20052594125
申请日期
2005.12.23
申请人
STICHTING KATHOLIEKE UNIVERSITEIT, THE UNIVERSITYMEDICAL CENTRE NIJMEGE N</
发明人
HESSELS, DAPHNE;SCHALKEN, JACK A.;VERHAEGH, GERALD;WITJES, ALFRED J.